Jaguar HealthFRA:1JA1 22 Piotroski F-Score is 6 as of Jun. 26, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates FRA:1JA1 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,342 Biotechnology companies, Jaguar Health ranks better than 92.03% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Jaguar Health has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Jaguar Health's Piotroski F-Score or its related term are showing as below:
FRA:1JA1'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 7
Current: 6
During the past 13 years, the highest Piotroski F-Score of Jaguar Health was 7. The lowest was 2. And the median was 4.
Jaguar Health (FRA:1JA1) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Jaguar Health Piotroski F-Score Related Terms
Jaguar Health Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Jaguar Health's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1JA1 vs BBLG, VBIO, PKTX: Piotroski F-Score Comparison
For the Biotechnology subindustry, Jaguar Health's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Jaguar Health's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Jaguar Health's current Net Income (TTM) was -29.16.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Jaguar Health's return on assets of this year was -0.61258403. Jaguar Health's return on assets of last year was -0.72312493.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Jaguar Health's gearing of this year was 0.26326091. Jaguar Health's gearing of last year was 0.34644036.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Jaguar Health's current ratio of this year was 0.49674651. Jaguar Health's current ratio of last year was 1.07910471.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Jaguar Health's number of shares in issue this year was 0.015. Jaguar Health's number of shares in issue last year was 0.018.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Jaguar Health's gross margin of this year was 0.85121827. Jaguar Health's gross margin of last year was 0.82362263.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Jaguar Health's asset turnover of this year was 0.53544118. Jaguar Health's asset turnover of last year was 0.21050669.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
1
+
0
+
1
+
1
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Jaguar Health has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Jaguar Health (FRA:1JA1) has a Piotroski F-Score of 6 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jaguar Health and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Jaguar Health's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Jaguar Health ranks #107 out of 1342 companies in the Biotechnology industry, placing it in the top 8%.
Is Jaguar Health's Piotroski F-Score too high?
Jaguar Health's current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. Jaguar Health's value of 6 is 100% above this industry median. Based on the distribution chart, Jaguar Health ranks #107 out of 1342 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jaguar Health has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's Piotroski F-Score compare to BBLG and VBIO?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #107 out of 1342 companies for Piotroski F-Score. This places Jaguar Health in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Jaguar Health's value of 6 is 100% above this benchmark. Historically, Jaguar Health's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Jaguar Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jaguar Health's current Piotroski F-Score of 6 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jaguar Health and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jaguar Health's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (FRA:1JA1) has a current Piotroski F-Score of 6. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 100% above the Biotechnology industry median of 3.00. Jaguar Health's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Jaguar Health (FRA:1JA1), the current Piotroski F-Score is 6 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
22GF Score
Get the complete analysis for FRA:1JA1
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JA1 has been successfully added to your 
